ERBB2 and breast cancer: Together, these results indicate that combination of HER2-DC i.t. and anti-HER2 antibodies increases the frequency of DC subsets in the TME, generates systemic antitumor immunity, and has the potential to attenuate the growth of distant tumors in HER2pos BC.